Niclosamide has been demonstrated with inhibitory activity on the replication of SARS-CoV in Vero E6 cells. This study examined the pharmacokinetics and oral bioavailability of niclosamide and its two analogs, BPR1H366 and BPRIH369, in male Sprague-Dawley rats. After a single 2-mg/kg intravenous dose, the total body clearance (CL) of niclosamide, BPR1H366 and BPR1H369 was 20.0±2.9, 26.7±4.4 and 39.4±6.7 mL/kg/min, and the volume of distribution at steady state (Vss) was 0.9±0.4, 0.3±0.1 and 1.1±0.2 L/kg, respectively. The half-life (t(subscript 1/2) of BPR1H366 and BPR1H369 was 2.6±0.3 and 3.7±1.1 hr, respectively, shorter than 6.7±2.0 hr of niclosamide. The AUC was 1413±118, 1019±203 and 750±113 ng/mL×hr for niclosamide, BPR1H366 and BPR1H369, respectively. After a single 5-mg/kg oral dose, all three compounds were rapidly absorbed. Niclosamide showed the highest C(subscript max) of 354±152 ng/mL within 30 min after oral gavage. The oral bioavailability of niclosamide, BPR1H366 and BPR1H369 was 10%, l2% and 15%, respectively. Our results demonstrated that the extents of drug exposure of the three compounds were comparable in rats. The pharmacokinetic properties of the compounds in humans are needed to be determined before their potential uses in SARS-CoV infected patients.
Niclosamide has been demonstrated with inhibitory activity on the replication of SARS-CoV in Vero E6 cells. This study examined the pharmacokinetics and oral bioavailability of niclosamide and its two analogs, BPR1H366 and BPRIH369, in male Sprague-Dawley rats. After a single 2-mg/kg intravenous dose, the total body clearance (CL) of niclosamide, BPR1H366 and BPR1H369 was 20.0±2.9, 26.7±4.4 and 39.4±6.7 mL/kg/min, and the volume of distribution at steady state (Vss) was 0.9±0.4, 0.3±0.1 and 1.1±0.2 L/kg, respectively. The half-life (t(subscript 1/2) of BPR1H366 and BPR1H369 was 2.6±0.3 and 3.7±1.1 hr, respectively, shorter than 6.7±2.0 hr of niclosamide. The AUC was 1413±118, 1019±203 and 750±113 ng/mL×hr for niclosamide, BPR1H366 and BPR1H369, respectively. After a single 5-mg/kg oral dose, all three compounds were rapidly absorbed. Niclosamide showed the highest C(subscript max) of 354±152 ng/mL within 30 min after oral gavage. The oral bioavailability of niclosamide, BPR1H366 and BPR1H369 was 10%, l2% and 15%, respectively. Our results demonstrated that the extents of drug exposure of the three compounds were comparable in rats. The pharmacokinetic properties of the compounds in humans are needed to be determined before their potential uses in SARS-CoV infected patients.
為了持續優化網站功能與使用者體驗,本網站將Cookies分析技術用於網站營運、分析和個人化服務之目的。
若您繼續瀏覽本網站,即表示您同意本網站使用Cookies。